Patents by Inventor Dorre A. GRUENEBERG

Dorre A. GRUENEBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods, compounds, and compositions for inhibition of ROS
    Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS
    Publication number: 20160031890
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Application
    Filed: March 14, 2013
    Publication date: February 4, 2016
    Inventors: Dorre A. GRUENEBERG, Ori KALID, Jun XIAN, Sharanappa B. RAJUR, Hwa-ok KIM, Venugopal Rao NEELAGIRI, Paresh GAONKAR, Divakaramenon MADHAVAN, Chaeho MOON, Madhavi NEELAGIRI
  • METHOD FOR MEASURING RESISTANCE OR SENSITIVITY TO DOCETAXEL
    Publication number: 20130252837
    Abstract: The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict of monitor patient's response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 26, 2013
    Applicant: Sanofi US
    Inventors: Dorre GRUENEBERG, Xi HUANG, Sridaran NATESAN, Paul AUGUST
  • Compositions and Methods for Inhibiting Tumor Growth
    Publication number: 20120208204
    Abstract: The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells.
    Type: Application
    Filed: June 3, 2010
    Publication date: August 16, 2012
    Applicants: The Brigham and Women's Hospital, Inc., Peresident and Fellows of Harvard College
    Inventors: Amy Baldwin, Dorre Grueneberg, Ed Harlow, Jun Xian, Karl Munger, Karin Hellner, Marcie Glicksman, Ross Stein, Gregory Cuny
  • Retroviral vectors for delivery of interfering RNA
    Patent number: 7884200
    Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: February 8, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Dorre Grueneberg, Gerard Bain, Nayantara Kothari
  • RETROVIRAL VECTORS FOR DELIVERY OF INTERFERING RNA
    Publication number: 20100028996
    Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.
    Type: Application
    Filed: October 7, 2009
    Publication date: February 4, 2010
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Dorre GRUENEBERG, Gerard BAIN, Nayantara KOTHARI
  • Retroviral vectors for delivery of interfering RNA
    Patent number: 7612195
    Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Dorre Grueneberg, Gerard Bain, Nayantara Kothari
  • METHOD FOR MEASURING RESISTANCE OR SENSITIVITY TO DOCETAXEL
    Publication number: 20090226894
    Abstract: The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict of monitor patient's response to a molecule of the taxoid family by measuring nucleid acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Dorre Grueneberg, Xi Huang, Sridaran Natesan, Paul August
  • Retroviral vectors for delivery of interfering rna
    Publication number: 20060252153
    Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.
    Type: Application
    Filed: October 21, 2004
    Publication date: November 9, 2006
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Dorre Grueneberg, Gerard Bain, Nayantara Kothari